Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Embolism

• RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
• The PEERLESS II Study
• 129Xe MRI Cardiopulmonary
• Supplemental Oxygen in Pulmonary Embolism (SO-PE)
• Comparison of Two Pulmonary Embolism Treatments
• Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
• Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
• Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
• Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
• Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism
• Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
• Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
• The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19
• Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
• A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
• A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
• A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
• Effect of iNO in Patients With Submassive and Massive PE
• In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection
• Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE)
• Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
• Pre- vs Postoperative Thromboprophylaxis for Liver Resection
• STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism
• Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
• Recombinant Non-immunogenic Staphylokinase VS Alteplase for Massive PE a Randomized Non-inferiority Trial
• Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
• Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
• Postoperative Thrombosis Prevention in Patients With CD
• Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)
• What is the Optimal Antithrombotic Strategy in Patients Presenting With Acute Coronary Syndrome Having Atrial Fibrillation With Indication for Anticoagulants?
• Pulmonary Embolism International THrOmbolysis Study-3
• Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
• Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
• Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
• Sildenafil in Acute Pulmonary Embolism
• Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
• tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
• Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
• Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
• Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)
• Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism
• PET Fibrin Imaging of DVT and PE
• Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE)
• Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
• Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
• Thrombolysis Endovascular Treatment of Pulmonary Embolism
• Screening for Cancer in Patients With Thromboembolic Disease
• Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease
• First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
• Chemoprophylaxis Plus Early Ambulation
• Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism
• Catheter Directed Interventions in Pulmonary Embolism
• Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
• Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin
• DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
• A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
• Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
• The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
• A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism
• Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
• Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
• PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
• Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI
• Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
• Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
• Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
• Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
• Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
• Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
• Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study
• A Different Approach to Preventing Thrombosis
• Radial Artery Occlusion After Endovascular Procedure
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
• A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
• Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
• Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients
• APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
• Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
• Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial
• Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
• Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
• A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
• An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant The
• Bioequivalence Study of Rivaroxaban
• Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
• Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive
• XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
• NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial
• LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke
• Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
• : Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
• An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
• Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
• Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
• Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
• Diuretic Versus Placebo in Pulmonary Embolism
• Use of Gadolinium in CT Pulmonary Angiography
• Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
• Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
• Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism
• Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
• Cancer Venous Thromboembolism (VTE)
• Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
• Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
• Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
• Nitric Oxide to Treat Pulmonary Embolism
• Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
• Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli
• The Study of Warfarin Maintenance Dose in Chinese Patients
• Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
• Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
• Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
• Anticoagulation Length in Cancer Associated Thrombosis
• AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
• Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
• Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
• Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
• Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI
• Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries
• Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis
• Diclofenac for Submassive PE
• Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation
• Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy
• Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
• Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
• Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
• A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
• Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism
• Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)
• Study Of Lybrel In Relation To Venous Thromboembolism
• Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis
• A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
• ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
• Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
• Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis
• Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
• Drug Interaction Between Paracetamol and Warfarin
• Epoprostenol in Pulmonary Embolism
• Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
• The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
• VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management
• Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
• Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer
• Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
• Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures
• A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
• Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism
• 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China
• Nadroparin for the Initial Treatment of Pulmonary Thromboembolism
• Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
• Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China
• Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery
• Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
• Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.
• Tinzaparin in the Treatment of the Acute Pulmonary Embolism
• Clot Dissolving Treatment for Blood Clots in the Lungs
• Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
• PEITHO Pulmonary Embolism Thrombolysis Study
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
• Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid
• Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon
• Inhaled Nitric Oxide in Pulmonary Embolism
• Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
• Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing
• Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
• Anticoagulant Therapy During Pacemaker Implantation
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
• Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
• Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
• Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
• Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
• Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
• Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
• Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
• Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
• An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
• Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
• Deferment of Imaging for Pulmonary Embolism
• Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy
• Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
• 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
• Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
• Detection of Pulmonary Embolism With CECT
• Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
• A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
• A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
• VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis
• Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
• D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
• Odiparcil For The Prevention Of Venous Thromboembolism
• Aortic Arch Related Cerebral Hazard Trial (ARCH)
• Aspirin for the Prevention of Recurrent Venous Thromboembolism
• Tenecteplase Pulmonary Embolism Italian Study
• The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
• Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
• The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial
• Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
• Fixed Dose Heparin Study
• PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism
• Genetic Determinants of Warfarin Anticoagulation Effect
• Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
• BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
• SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
• SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
• Treatment for Blood Clots in the Veins of the Legs
• Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)